Table 1

Characteristics of the participants who reported using a DMT in at least one of the 2015, 2016 and 2017 Australian Multiple Sclerosis Longitudinal Study medication and disease course surveys

201520162017Total observations
Total observations, n10898269022817
Treatment
Category 1 DMTs, n (%)
 Interferon β-1b98 (9.0)60 (7.3)54 (6.0)212 (7.5)
 Interferon β-1a SC47 (4.3)39 (4.7)38 (4.2)124 (4.4)
 Interferon β-1a IM70 (6.4)43 (5.2)37 (4.1)150 (5.3)
 Pegylated interferon β-1a44 (4.0)41 (5.0)55 (6.1)140 (5.0)
 Glatiramer acetate147 (13.5)114 (13.8)109 (12.1)370 (13.1)
Category 2 DMTs, n (%)
 Teriflunomide63 (5.8)58 (7.0)79 (8.8)200 (7.1)
 Dimethyl fumarate142 (13.0)96 (11.6)96 (10.6)334 (11.9)
Category 3 DMTs, n (%)
 Natalizumab124 (11.4)102 (12.3)118 (13.1)344 (12.2)
 Fingolimod330 (30.3)237 (28.7)283 (31.4)850 (30.2)
 Alemtuzumab23 (2.1)36 (4.4)33 (3.7)92 (3.3)
 Mitoxantrone1 (0.1)0 (0.0)0 (0.0)1 (0.0)
Age (years), mean (SD)51.92 (10.5)52.40 (10.6)53.46 (9.9)52.55 (10.4)
MS duration since diagnosis (years), mean (SD)12.26 (7.2)12.18 (7.4)12.24 (7.1)12.23 (7.2)
Sex, n (%)
 Female883 (81.1)666 (80.6)732 (81.2)2281 (81.0)
 Male206 (18.9)160 (19.4%)170 (18.8)536 (19.0)
Highest education, n (%)
 Primary or secondary school278 (25.5)195 (23.6)233 (25.8)706 (25.1)
 Occupational certificate or diploma374 (34.3)284 (34.4)295 (32.7)953 (33.8)
 University bachelor’s degree254 (23.3)200 (24.2)215 (23.8)669 (23.7)
 University postgraduate degree183 (16.8)147 (17.8)159 (17.6)489 (17.4)
MS type at survey time, n (%)
 Relapsing–remitting MS920 (84.5)702 (85.0)740 (82.0)2362 (83.8)
 Secondary progressive MS105 (9.6)79 (9.6)101 (11.2)285 (10.1)
 Primary progressive MS64 (5.9)45 (5.4%)61 (6.8)170 (6.0)
  • DMT, disease-modifying therapy; IM, Intramuscular; MS, multiple sclerosis; SC, Subcutaneous.